Chengzhi Huang, Mengya Yu. Guangdong General Hospital (Guangdong Academy of Medical Science)
Keywords: microRNA-17; Cancer; Outcome; Prognosis; Meta-analysis.
Background: The recognition of biomarkers to predict the outcome of caner is in need. MicroRNA-17 (miR-17) family has been thoroughly studied and reported to contribute to the progress of human carcinomas. miR-17 is one of the most important miR-17 family member, and has been reported as a tumor biomarker by various researches. However, the prognostic value of miR-17 in cancers remains unclear. Therefore, we put up with a systemic review and meta-analysis to summarize and analyze the relationship between the miR-17 status and clinical outcome in several kinds of human cancers.
Methods: Published articles associated with miR-17 and clinical outcome of cancers were screened by searching the online databases of PubMed, Web of Science, Embase, China Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Technology of Chongqing (VIP) and Wan Fang databases. The patients’ survival results were pooled, and pooled hazard ratio (HR) with 95% confidential intervals (95% CI) were calculated and used for measuring the strength of association between miR-17 and the prognosis of cancers, including hepatocellular carcinoma (HCC), lung cancer, osteosarcoma, glioma, T-cell lymphoblastic lymphoma and colon cancer (CC). Heterogeneity, publication bias and subgroup analysis were also conducted.
Results: The systematic review and meta-analysis is registered in PROSPERO (No. CRD42017065749). In all 12 articles, totally 1096 patients were included in this meta-analysis. The results indicated that the increased expression of miR-17 played an unfavorable role in overall survival (OS) in various human carcinomas with the HR of 1.342 (95% CI=1.238-1.456) concerning the publication bias. In subgroup analysis, HR of ethnicity (Caucasian HR=1.48 and Asian HR=1.40), disease (digestive system HR=1.36 and non-digestive system HR=1.54), detection method (qRT-PCR HR=1.40 and in situ hybridization, ISH HR=2.59) and detection sample (tissue HR=1.45 and serum HR=1.32), all p < 0.05. On the analysis of disease-free survival (DFS) and recurrence-free survival (RFS), the unfavorable prognosis role was also found with the increased expression of miR-17 (HR=1.40, 95% CI=1.23-1.60).
Conclusions: miR-17 might be a useful biomarker in predicting the clinical outcome of human cancers.
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 86162
Program Number: P075
Presentation Session: iPoster Session (Non CME)
Presentation Type: Poster